The agreement with a large network of hospitals is directly related to Nuwellis's core product, Aquadex Ultrafiltration Therapy, which is likely to increase its adoption and usage. This could lead to increased revenues and a stronger market position for Nuwellis. The lack of disclosed financial terms adds some uncertainty to the exact financial impact, but the scale of the agreement suggests a positive outlook.